Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
98
resultados
Última actualización
04/11/2026 [08:53:00]
Resultados 50 a 75 de 98
Resumen de: KR20260126133A
0001a 염증성 장질환(inflammatory bowel disease, IBD) 치료용 세포 치료제 약효 평가 방법 및 스크리닝 방법에 관한 것으로, 보다 상세하게는 인간 PBMC로 인간화한 IBD 동물에 세포 치료제를 투여하여 개선 효과를 확인하는 단계를 포함하는 IBD 치료용 세포 치료제 약효 평가 방법 및 스크리닝 방법에 관한 것이다. 본 발명에 따르면, 사람 유래 말초혈액 단핵세포(PBMC)를 이용하여 인간화된 동물모델에서 염증성 장질환(IBD)을 유도하고, 해당 모델에서 세포 치료제의 효능을 평가함으로써, 인간 특이적 면역 반응을 반영한 세포 치료제의 예방 또는 치료 효과를 보다 정밀하게 검증할 수 있다. 이에 따라, 종래의 일반적인 동물모델에서는 재현하기 어려웠던 인간 면역계 기반의 염증 반응 및 치료 반응을 효과적으로 평가할 수 있다.
Resumen de: CN122588232A
0001 本发明属于生物技术领域，尤其涉及克罗恩病肠系膜脂肪外泌体在评估克罗恩病肠道纤维化水平及构建克罗恩病肠道纤维化动物模型中的用途。miR‑184可作为克罗恩病伴发肠道纤维化的风险评估标志物，还可作为干预克罗恩病动物模型的工具以干预肠道纤维化等水平。NCOR2蛋白可作为克罗恩病伴发肠道纤维化的风险评估标志物，还可作为干预克罗恩病动物模型的工具以干预肠道纤维化等水平。本公开验证了基于上述两个靶点构建克罗恩病伴肠道纤维化实验模型方案的可行性，为深化克罗恩病相关研究，尤其是加深对克罗恩病继发肠道纤维化病理进程的认知提供了支撑。
Resumen de: CN122588228A
本发明属于生物医药技术领域，具体而言，涉及一种克罗恩病肠道纤维化标志物及应用。本发明公开了一种定量检测IL4I1表达水平的试剂或试剂盒在制备用于预后评估、诊断或监测克罗恩病肠道纤维化产品中的应用。本发明旨在揭示CD肠道纤维化发生的分子机制，并探究其靶向治疗策略，为临床上CD肠道纤维化的预防与治疗提供理论与实验基础。
Resumen de: US20260234724A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: AU2025213436A1
Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.
Resumen de: WO2025075714A1
Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.
Resumen de: CN122545808A
0001 本发明属于生物传感与体外诊断技术领域，具体涉及一种用于粪便钙卫蛋白含量检测的试剂盒及方法。该方法利用柠檬酸钠还原法制备金纳米粒子（AuNPs），并将其与特异性识别钙卫蛋白的核酸适配体结合。在无靶标存在时，适配体通过静电和空间位阻保护AuNPs免受盐离子诱导的聚集；当待测样本中存在钙卫蛋白时，适配体优先与靶标结合而从AuNPs表面脱落，随后在一定浓度的盐离子作用下，失去保护的AuNPs发生聚集，溶液颜色由红色变为蓝色。本发明通过紫外‑可见吸收光谱或智能手机图像RGB通道即可实现对钙卫蛋白的灵敏定量检测。该方法无需昂贵的抗体和大型精密仪器，具有成本低、稳定性好、响应快、特异性高等优点，适合于炎症性肠病的基层筛查与居家即时检测。
Resumen de: CN122555573A
Some aspects of the present disclosure provide compositions and methods for treating a subject suffering from an inflammatory bowel disease, the methods comprising administering to the subject a hemopoietin (HJV) antagonist (e.g., an anti-HJV antibody).
Resumen de: CN122545821A
本发明提供一种IL‑11rα1在肠纤维化诊断产品和药物中的应用。属于体外诊断和生物医药交叉技术领域。具体而言，本发明提供了一种肠纤维化诊断产品，所述肠纤维化诊断产品包括IL‑11rα1检测试剂，本发明证明了IL‑11rα1可作为炎症性肠病所致的肠纤维化的诊断标志物和治疗靶点。为肠纤维化的临床诊断和治疗提供了新工具，具有广阔的应用前景。
Resumen de: CN122537358A
The invention relates to a pig model construction method for simulating the intestinal state of irritable bowel syndrome, and belongs to the technical field of biology. The invention provides a construction method of an irritable bowel syndrome animal model, which constructs the irritable bowel syndrome animal model by alternately lavage omeprazole and fecal bacteria liquid of an irritable bowel syndrome patient to a pig every other day, and can comprehensively simulate multi-dimensional pathological characteristics of the irritable bowel syndrome. The simulation degree of the model on the intestinal state of the human irritable bowel syndrome and the stability of the model are improved. The method can be further used for drug screening and drug effect evaluation of the irritable bowel syndrome, and development and research of biomarkers related to the irritable bowel syndrome.
Resumen de: CN122545796A
The invention discloses an application of a TAT3/ZBP1 signal channel as a drug target in screening of an anti-ulcerative colitis drug, and discloses that in ulcerative colitis (UC), a transcription factor STAT3 is directly combined with a ZBP1 gene promoter region and expression of ZBP1 is up-regulated, so that RIPK1/RIPK3/MLKL mediated intestinal epithelial cell necroptosis is activated, and intestinal inflammation is aggravated for the first time. According to the invention, the STAT3/ZBP1 signal channel is determined as an effective target for screening ulcerative colitis drugs, and a new screening strategy and evaluation system are provided for developing necroptosis-targeted ulcerative colitis treatment drugs.
Resumen de: CN122516340A
本发明提供了CXCL2在炎症性肠病中的应用。本发明研究发现CXCL2在炎症性肠病患者的肠道粘膜组织和血清中以及结肠炎小鼠肠道组织中表达均显著上调，CXCL2可能在炎症性肠病中发挥重要功能；CXCL2通过提高中性粒细胞募集，释放大量的炎性细胞因子IL‑1β和TNF‑α，引起肠道炎症；因此，可通过降低CXCL2基因表达水平来降低肠道中中性粒细胞募集，进而抑制IL‑1β和TNF‑α的大量释放，从而达到保护宿主减轻炎症性肠病损伤的重要作用。
Resumen de: US20260227396A1
0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: WO2026162782A1
The present invention relates to a method for the prediction of the risk of recurrence of Crohn's disease (CD) after intestinal resection and anastomosis in a human subject based on the measure of the expression level of GPX4.
Resumen de: AU2025224860A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: CN122502456A
0001 本发明属于兽医生物技术与免疫检测技术领域。更具体地，涉及胞内劳森菌新型分子靶标在检测猪血清中胞内劳森菌特异性抗体方面的应用。本发明筛选并提供了一种胞内劳森菌特异性蛋白group_1439，该蛋白具备优异的免疫反应性与抗原结合特异性，能被胞内劳森菌特异性抗体高效识别。基于该蛋白，本发明建立了一种间接ELISA 抗体检测方法，可检测胞内劳森菌特异性抗体，该方法具备高敏感性、高特异性及良好的重复性。本发明克服了部分进口试剂盒假阳性率高或灵敏度波动的问题，为我国胞内劳森菌的流行病学调查、猪增生性回肠炎的早期诊断及综合防控提供了可靠的国产化技术支撑，具有良好的临床符合率与进口替代潜力。
Resumen de: CN122503497A
The invention relates to the technical field of biological medicine, in particular to a marker for ulcerative colitis and application, and aims to solve the problems that in the prior art, UC prediction markers and standardized diagnosis models are lacked, the marker for ulcerative colitis is composed of SRGN, CCL4, CD93, CTSK and SERPINA3, the marker can be used for preparing a product for diagnosing the ulcerative colitis, constructing a diagnosis model of the ulcerative colitis occurrence risk, and substituting the expression level of the marker in a biological sample of a subject into the diagnosis model, so that the illness probability of the ulcerative colitis can be calculated, and therefore, auxiliary diagnosis and risk prediction of the ulcerative colitis can be realized. The quantitative evaluation of the disease probability of ulcerative colitis is realized, the recognition accuracy of ulcerative colitis is greatly improved, and a reliable basis is provided for clinical early discovery and early intervention.
Resumen de: WO2026161796A1
The present disclosure relates to the use of biomarkers, e.g., TNF-α, IL-17F, GM-CSF, and combinations thereof, to identify the responsiveness of IBD patients to treatment with an anti-IL23 antagonist (e.g., anti-IL23 antibodies). The levels of biomarkers are compared to the levels of the same biomarkers in an individual having a known responsiveness status. Information provided by the disclosed method may be used to determine whether an IBD patient should be treated with an IL-23 antagonist or a treatment that does not target IL-23. Such information may also be used to determine if treatment with a certain agent should be commenced, suspended, or modified. Also disclosed herein are methods of determining the level of a biomarker associated with responsiveness of an individual to treatment with an IL-23 antagonist.
Resumen de: US20260219282A1
0000 Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in the methods of immunoassay.
Resumen de: US20260217813A1
The present invention relates to an antibody for treating or preventing autoimmune diseases. The antibody of the present invention comprises a heavy chain variable region set forth in SEQ ID NO:1 or SEQ ID NO:24 and a light chain variable region set forth in SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17 or SEQ ID NO:25.
Resumen de: AU2025224738A1
The present invention relates to methods of immunoassay for detecting or monitoring inflammatory bowel disease or a severity thereof in a patient. In certain embodiments, the inflammatory bowel disease may be ulcerative colitis.
Resumen de: US20260218299A1
0000 Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.
Resumen de: US20260219280A1
Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Resumen de: CN122461392A
The granules are prepared from 11 raw material medicines including codonopsis pilosula, bighead atractylodes rhizome, poria cocos, wintercreeper, sanguisorba officinalis, herba lycopi and the like according to specific parts by weight, mixed auxiliary materials of dextrin and soluble starch (the mass ratio is 2: 1) are supplemented, and the dosage of the auxiliary materials accounts for 20%-30% of the total solid content of extract. The preparation process comprises the following steps: crushing the medicinal materials into coarse powder, adding 12 times of water, decocting twice (1 hour each time), and collecting volatile oil; and filtering the decoction, concentrating to obtain an extract with the relative density of 1.10-1.15 at 60 DEG C, adding auxiliary materials to prepare a soft material, sieving with a 16-mesh sieve, granulating, drying at 60 DEG C or below until the water content is less than or equal to 8.0%, finally dissolving volatile oil with ethanol, spraying into the granules, and uniformly mixing. The critical relative humidity of the granules is 77.35%, the quality detection adopts thin layer chromatography to identify medicinal materials such as bighead atractylodes rhizome and the like, and high performance liquid chromatography is adopted to determine the content of gallic acid (not less than 1.20 mg per 15g). The traditional Chinese medicine composition is scientific in compatibility, clear in process parameters, controllable in quality and suitable for t
Nº publicación: CN122468979A 28/07/2026
Solicitante:
SICHUAN PROVINCIAL PEOPLES HOSPITAL SICHUAN ACAD OF MEDICAL SCIENCES
\u56DB\u5DDD\u7701\u533B\u5B66\u79D1\u5B66\u9662\u00B7\u56DB\u5DDD\u7701\u4EBA\u6C11\u533B\u9662
Resumen de: CN122468979A
The invention discloses application of a reagent for detecting a biomarker in preparation of a product for predicting the activity of ulcerative colitis disease or a product for diagnosing ulcerative colitis disease, and relates to the technical field of inflammatory bowel disease serological markers. The serum CD105 of UC patients is obviously higher than that of a healthy control group, and the CD105 has an extremely high effect of diagnosing ulcerative colitis diseases and can distinguish disease activity from disease relief. Therefore, the invention provides a novel serum marker which is convenient to sample, good in repeatability and capable of objectively reflecting the inflammation load of the colonic mucosa, and more accurate marker selection is expected to be provided for UC disease activity prediction and UC diagnosis.
BOPI
Sede Electrónica
